Recent in vivo studies of Alisterib in MYC-overexpressing lymphoma xenografts demonstrated synthetic lethality by caspase-independent cell death and complete tumor regression when paired with chemotherapy cyclophosphamide [196]. This evidence concerns the gene MYC and neoplasm.